Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 27 of 27 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01396408	Phase II	Temsirolimus Sunitinib	A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	Active, not recruiting	CAN	0
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT03624543	Phase II	CFI-400945	CFI-400945 in Patients With Advanced/Metastatic Breast Cancer	Active, not recruiting	CAN	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Active, not recruiting	USA	0
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Active, not recruiting	USA	0
NCT01226316	Phase I	Capivasertib	Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| CAN	2
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Completed	USA	0
NCT01470209	Phase I	Buparlisib + Everolimus	A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies	Completed	USA	0
NCT01971515	Phase I	M2698	First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies	Completed	USA	0
NCT03207347	Phase II	Niraparib	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Completed	USA	0
NCT03337724	Phase II	Ipatasertib + Paclitaxel Paclitaxel	A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130)	Completed	USA \| TUR \| SVN \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	13
NCT03834740	Phase I	Everolimus + Ribociclib	A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Completed	USA	0
NCT04774952	Phase I	RMC-5552	Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors	Completed	USA	0
NCT04958226	Phase I	Capivasertib + Midazolam	A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours	Completed	USA	0
NCT02523014	Phase II	Abemaciclib GSK2256098 Vismodegib Capivasertib	Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas	Recruiting	USA	0
NCT05563220	Phase Ib/II	Alpelisib + Elacestrant Elacestrant + Ribociclib Elacestrant + Everolimus Elacestrant + Palbociclib Abemaciclib + Elacestrant Capivasertib + Elacestrant	Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer (ELEVATE)	Recruiting	USA \| TUR \| POL \| LUX \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| BRA \| BEL \| AUS \| ARG	1
NCT05773326	Phase I	Temsirolimus	Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG	Recruiting	USA	0
NCT05933395	Phase II	Abemaciclib + Fulvestrant Fulvestrant + Neratinib Alpelisib + Fulvestrant Everolimus + Fulvestrant	Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (GERTRUDE)	Recruiting	USA	0
NCT06738303	Phase II	lutetium Lu 177 vipivotide tetraxetan Cabazitaxel + Carboplatin	Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer (CATCH-177)	Recruiting	USA	0
NCT07062965	Phase III	Everolimus + Fulvestrant Everolimus + Exemestane Fulvestrant + PF-07248144	A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.	Recruiting	USA	2
NCT01870726	Phase Ib/II	Buparlisib + Capmatinib	Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma	Terminated	USA \| NLD \| ESP \| DEU \| CHE	0
NCT02315625	Phase II	Everolimus Sunitinib	Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery	Terminated	USA	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT02644122	Phase II	SF1126	SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes	Terminated	USA	0
NCT02987959	Phase II	Sapanisertib	Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas	Terminated	USA	0
NCT04586270	Phase I	TAS0612	A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer	Terminated	USA \| FRA	0
NCT04042831	Phase II	Olaparib	Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	Unknown status	USA	0

Showing 1 to 27 of 27 entries

Filter rows:

Profile Name	PTEN mutant
Gene Variant Detail	PTEN mutant (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting